Axonics, Inc. (NASDAQ:AXNX) Shares Acquired by AQR Capital Management LLC

AQR Capital Management LLC increased its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 0.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,337 shares of the company’s stock after acquiring an additional 161 shares during the quarter. AQR Capital Management LLC’s holdings in Axonics were worth $1,233,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. KRYGER CAPITAL Ltd acquired a new stake in shares of Axonics in the first quarter valued at approximately $65,211,000. Magnetar Financial LLC increased its holdings in shares of Axonics by 218.3% during the first quarter. Magnetar Financial LLC now owns 1,146,019 shares of the company’s stock valued at $79,041,000 after purchasing an additional 785,981 shares during the period. Absolute Gestao de Investimentos Ltda. acquired a new position in shares of Axonics during the second quarter valued at $32,681,000. Alpine Associates Management Inc. raised its stake in shares of Axonics by 16.2% during the second quarter. Alpine Associates Management Inc. now owns 2,108,871 shares of the company’s stock valued at $141,779,000 after purchasing an additional 294,100 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. acquired a new stake in Axonics in the first quarter worth about $16,573,000. Institutional investors own 99.48% of the company’s stock.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “hold” rating on shares of Axonics in a research report on Monday, August 5th. Eight equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $69.57.

Insider Buying and Selling at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total transaction of $205,523.01. Following the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at $2,801,526.42. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.85% of the company’s stock.

Axonics Stock Performance

Axonics stock opened at $70.30 on Friday. The firm has a market cap of $3.59 billion, a price-to-earnings ratio of -1,757.06 and a beta of 0.82. Axonics, Inc. has a 1 year low of $48.30 and a 1 year high of $70.53. The firm’s 50 day moving average price is $69.11 and its two-hundred day moving average price is $68.11.

Axonics (NASDAQ:AXNX) last announced its earnings results on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The company had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. Axonics’s revenue for the quarter was up 23.3% compared to the same quarter last year. As a group, equities analysts predict that Axonics, Inc. will post 0.24 EPS for the current fiscal year.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.